Ipsen appoints Beniot Hennion as president of primary care

2 March 2017

French drugmaker Ipsen (Euronext: IPN) has appointed Benoit Hennion as executive vice president and president of primary care.

Mr Hennion, who will join the executive leadership team at Ipsen and will report directly to chief executive David Meek, replaces Jean Fabre, who will take up a position at another company.

Mr Hennion joined Ipsen in 2006, becoming head of the French primary care business unit in 2009. He became general manager of French operations in 2011, including both specialty and primary care. He was appointed vice president of Asia-Pacific specialty care in 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK